Osteoporosis as a first manifestation of systemic mastocytosis. Study of 6 cases;Osteoporosis como primera manifestación de una mastocitosis sistémica. Estudio de 6 casos

Medicina Clinica

Volumn 128, Issue 6, 2007, Pages 216-218

  Sallés, Meritxell ^a,c   Holgado, Susana ^b   Navarro, José Tomás ^b   Ribera, Josep Maria ^b   Riera, Elena ^b   Millà, Fuensanta ^b   Tena, Xavier ^b  

^a HOSPITAL CLÍNIC   (Spain)

^b HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^c CAP Bages   (Spain)

Author keywords

Bisphosphonates; Secondary osteoporosis; Systemic mastocytosis

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; PARATHYROID HORMONE[1-34];

ADULT; AGED; ARTICLE; BONE DENSITY; CLINICAL ARTICLE; DRUG RESPONSE; FEMALE; FRACTURE; GASTROINTESTINAL DISEASE; HEMATOLOGIC DISEASE; HISTAMINE BLOOD LEVEL; HUMAN; MALE; OSTEOPOROSIS; SKIN MANIFESTATION; SYSTEMIC MASTOCYTOSIS; URINALYSIS; VERTEBRA FRACTURE;

EID: 33847710717     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0025-7753(07)72541-1     Document Type: Article

References (16)

1. Valent P, Horny HP, Escribano L, Jack Longley B, Li CY, Schwartz LB, et al. Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res. 2001;25:603-25.
2. Vargas-Manchuca I. Mastocitosis sistémica y afectación ósea. Reemo. 2002;11:109-12.
3. Schneider A, Shane E. Osteoporosis secondary to illnesses and medications. En: Marcus R, Feldman D, Kelsey J, editores. Osteoporosis. San Diego: Academic Press; 2001. p. 308-9.
4. Travis WD, Li CY, Bergstralh EJ, Yam LT, Swee RG. Systemic mast cell disease. Analysis of 58 cases and literature review. Medicine (Baltimore). 1988;67:345-68.
5. Sánchez-Montero MB, Vaquero Roncero LM, Arias Paciencia M, Rodríguez Robina PF. Mastocitosis ósea. Aproximación al diagnóstico. An Med Interna (Madr). 2000;17:267-73.
6. Chines A, Pacifici R, Avioli LV, Teitelbaum SL, Korenblat PE. Systemic mastocytosis presenting as osteoporosis: a clinical and histomorphometric study. J Clin Endocrinol Metab. 1991;72:140-4.
7. Marshall A, Kavanagh RT, Crisp AJ. The effect of pamidronate on lumbar spine bone density and pain in osteoporosis secondary to systemic mastocytosis. Br J Rheumatol. 1997;36:393-6.
8. Lim AYN, Ostor AJK, Crisp AJ. Systemic mastocytosis: a rare cause of osteoporosis and its response to bisphosphonate treatment. Ann Rheum Dis. 2005;64:965-6.
9. World Health Organization. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rep Ser. 1994;843:1-129.
10. Raisz LG. Local and systemic factors in the pathogenesis of osteoporosis. N Engl J Med. 1988;318:818-28.
11. Gradel B, Flautre B, Sutter B, Duriez J, Hardouin P. [Study of mastocytes in 1298 bone biopsies. Relationship between mastocytes and osteoporosis]. Rev Rheum Mal Osteoartic. 1991;58:759-61.
12. Brumsen C, Papapoulos SE, Lentjes EG, Kluin PM, Hamdy NA. A potential role for the mast cell in the pathogenesis of idiopathic osteoporosis in men. Bone. 2002;31:556-61.
13. Cundy T, Beneton MNC, Darby AJ, Marshall WJ, Kanis JA. Osteopenia in systemic mastocytosis: natural history and responses to treatment with inhibitors of bone resorption. Bone. 1987;8:149-55.
14. Delling G, Ritzel H, Werner M. Histological characteristics and prevalence of secondary osteoporosis in systemic mastocytosis. A retrospective analysis of 158 cases. Pathologie. 2001;22:132-40.
15. Weide R, Ehlenz K, Lorenz W, Walthers E, Klausmann M, Pfluger KH. Successful treatment of osteoporosis in systemic mastocytosis with interferon alpha-2b. Ann Hematol. 1996;72:41-3.
16. Droogendijk HJ, Kluin-Nelemans HJ, Van Doormaal JJ, Oranje AP, Van de Loosdrecht AA, Van Daele PL. Imatinib mesylate in the treatment of systemic mastocytosis. Cancer. 2006;107:345-51.